Researchers of the German Center for Infection Research (DZIF) at the Paul-Ehrlich-Institut (PEI) and Philipps-Universität Marburg used the "recombinant measles virus" vaccine platform to test vaccine
The Else Kröner-Fresenius Foundation's ForTra gGmbH for Research Transfer—the largest medicine-funding foundation in Germany—supports the legally compliant production of new drug candidates for direct
In a multicentre phase 3 trial, researchers at the MHH have demonstrated the efficacy and safety of the drug Bulevirtide, which prevents Hepatitis D viruses from entering the liver.
Antibiotics affect the composition and dynamics of the gut microbiome. Treatment with antibiotics not only leads to a loss of biodiversity of microorganisms, but also often favours the selection of
The drug candidate BTZ-043 has a novel mechanism of action and belongs to a new class of substances. Discovered at the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI
It was previously believed that herpesviruses use certain body cells to replicate and other body cells to remain dormant, that is to remain inactive for a longer period of time. This dogma is now
Every year at least 700,000 people die as a result of infection with antibiotic-resistant bacteria—a figure which according to WHO forecasts could rise to ten million people by 2050 without new
The German Center for Infection Research (DZIF) is again offering the DZIF Prize for Translational Infection Research. Scientists can apply to the DZIF Academy until 15 August 2023. A prize of 5,000
Researchers at the University Medical Center Hamburg-Eppendorf have demonstrated cross-reactive immune responses to another SARS-CoV-2 protein besides the spike protein. The research team found a
The incubator INCATE (INCubator for Antibacterial Therapies in Europe) was founded by a consortium of academic institutions—including the German Center for Infection Research (DZIF)—and industrial